June 13, 2025

RSV Vaccine Approved for Younger Adults

The FDA has approved Moderna’s mRESVIA vaccine for adults aged 18 to 59 who are at increased risk for RSV, expanding its indication beyond older adults.

Conexiant

June 06, 2025

FDA Monthly Round-up: Key May Updates

May’s FDA approvals include the first at-home HPV test, a blood-based Alzheimer’s diagnostic, biosimilars, AI-enabled imaging tools, and novel therapies across cardiology, pulmonology, neurology, gastroenterology, and more.

Conexiant

June 06, 2025

RSV or COVID: Which Strains the Heart?

A study of 32,960 hospitalizations finds 10.9% of patients with RSV experienced acute cardiovascular events, with significantly higher adjusted odds than boosted and unboosted COVID-19 cases.

Conexiant

June 04, 2025

Big Tobacco's Medical Research Infiltrates Journals

Investigation reveals tobacco-funded studies appear in top medical journals despite industry bans, as companies invest billions in pharmaceutical subsidiaries.

Conexiant

June 02, 2025

New COVID Vaccine Approved for High-Risk Groups

After showing higher efficacy and a comparable safety profile to Spikevax, the FDA has approved Moderna’s mNEXSPIKE COVID-19 vaccine for high-risk patients.

Conexiant

May 30, 2025

Mepolizumab Reduces COPD Flares in Eosinophilic Patients

A new clinical trial found that adding mepolizumab to standard inhaled therapy significantly reduced moderate or severe COPD exacerbations in patients with high eosinophil counts, with a 21% lower annual rate and longer time to first flare.

Conexiant

May 29, 2025

Physical Disease Clusters Predict Future Depression Risk

A large UK study found that people with multiple physical health conditions face a significantly higher risk of developing depression, with risk levels varying by type and number of conditions.

Conexiant

May 28, 2025

Kennedy Proposes NIH Publishing Ban

"We're probably going to stop publishing in The Lancet, New England Journal of Medicine, JAMA, and those other journals because they're all corrupt."

Conexiant

May 28, 2025

Study Finds Low RSV Vaccine Uptake Among Older Adults

A new multicenter analysis of over 6,700 hospitalized older adults found that RSV vaccine uptake was low in its first season, with significant gaps in awareness and access, especially among socioeconomically vulnerable populations.

Conexiant